Genopole Partnering Week 2026

• Abolis Biotechnologies

  #Ag/Clean/GreenTech #Foodtech #Healthtech

  Abolis Biotechnologies is a French biotechnology company specialising in microbial systems and industrial-grade biotech applications for the food, cosmetics, healthcare and chemical industries. The company helps innovators, manufacturers and R&D teams understand complex microbial systems and address critical industrial challenges through ingredient and biotics development, process optimisation and product innovation. Combining expertise in strain engineering, microbial metabolism, fermentation and bioprocess development with proprietary

  Maturity: Pilote Prototype
  Keywords: Biotech – food & agriculture, Biotech – industrial & environmental, Biotech or pharma, therapeutic R&D

  

• ADVANCED CARE TECHNOLOGIES

  #Healthtech
  Advanced Care Technologies develops non-invasive solutions to compensate for sensory loss. Our innovation converts pressure data into haptic feedback, helping restore a form of sensation for amputees, with future applications in other sensory disorders such as diabetic foot prevention. We are seeking collaborations in funding, R&D, licensing, industrialisation and commercialisation.

  Maturitéy: Preclinical
  Recherche de fonds : Pre-Seed
  Mots clés : Medical device, amputation, diabetes, sensory feedback, autonomy

  

• AFFINEO

  #Foodtech
  Affineo is a biotech platform engineering ultra-stable proteins for environments where ordinary proteins fail. Using in vivo evolution in thermophiles, we generate proteins that withstand heat, processing, and harsh formulations. We enter the market through a Fel d 1 binder for wet pet food, where current solutions break down. From there, the platform extends to other stability-demanding applications, from further allergens to broader industrial and therapeutic targets.

  Maturity: POC
  Fundraising : Pre-Seed
  Keywords: Protein Engineering, FoodTech, Platform, Hyperstability, Additives

  

• Algenscribe

  #Healthtech

  Algenscribe develops a Gene Editing platform to improve the efficiency and quality of Gene Replacement.
  The platform finds applications in the fields of Gene Therapy, oncology and bioproduction.

  Maturity: POC
  Fundraising Seed
  Keywords: Gene Therapy, Gene editing

  

• BCV Care

  #Healthtech

  Bacterial infections are generally treated with antibiotics, which lead to the development of resistance (AMR), posing a major global health challenge. For humans and animals, policies tend to reduce the use of antibiotics and innovation is rare. Furthermore, very few effective vaccines are available.
  BCV Care aims to become a global leader in the fight against AMR thanks to its unique WINA platform for highly effective inactivated antibacterial vaccines.

  Maturity: POC
  Fundraising: Seed
  Keywords: Biotech, vaccines

• BIOTISSUE TECHNOLOGIES

  #Healthtech

  BioTissue develops innovative regenerative medicine implants, with a focus on orthopaedic applications. Our lead product, Chondrotissue, is an implant for cartilage repair and has achieved CE mark in Europe and Breakthrough Device Designation from the US-FDA.

  Maturity: Registration/Marking
  Keywords: Implants, Regenerative Medicine

  

   

• CGENETIX

  #Diagnostic

  CGenetix is developing a new non-invasive in vitro medical device to quantify organ damage during a pathological process such as transplant rejection. Focusing first on kidney transplantation, we plan to become in the next decade one of the European leaders in cfDNA for the medical follow-up of transplant patients.

  Maturity: Clinique
  Fundraising: Seed
  Keywords: Diagnostics

  

• DEMETIS

  #Ag/Clean/GreenTech
  At Demetis, we develop a safe and efficient alternative to pesticides helping farmers to protect their crops from viral diseases. Our technology is based on the use interfering RNA which allows a specific and precise elimination of viruses as soon as they enter the plant. We are also working on an encapsulation and spraying method of this active component.

  Maturity: Prototype labo
  fundraising: Seed
  Keywords: Synthetic biology, plant biology, agriculture, RNA interference, viruses

• DROPO LABS

  #Ag/Clean/GreenTech #Diagnostic
  Dropo Labs is developing a new generation of PCR instruments, faster and more affordable.
  The technology is based on years of microfluidics research and targets central medical analysis laboratories as well as the Agri and Biotech industries, where PCR is widely used.

  Maturity: POC
  Fundraising: Pre-Seed
  Keyword: Diagnostic

• EPICS BIOTECHNOLOGY

  #Ag/Clean/GreenTech

  EPICS Biotechnology is an innovative company specializing in synthetic biology, developing next-generation solutions for sustainable agriculture and bio manufacturing.
  Our mission is to harness the natural biosynthetic capabilities of plants particularly Camelina sativa to efficiently and sustainably produce high-value biomolecules at scale, using natural compounds and techniques such as CRISPR-Cas9 and transgenesis.

  Maturity: Pilot Prototype
  Fundraising: Seed
  Keywords: Plant biotech, agritech, synthetic biology

  

• Genosafe

  #Healthtech

  GenoSafe has a unique expertise in the development and validation of quality control tests for gene therapy vectors and cell therapy products. Genosafe also offers bioanalysis services for preclinical and clinical samples in the context of (pre)clinical trials of gene and cell therapy products.

  Keywords: Cell & Gene Therapy

  

• HERELLIBIO

  #Ag/Clean/GreenTech

  HerelliBio is developing a platform of programmable biological particles inspired by viruses, designed to target and neutralize pathogenic fungi. Produced through synthetic biology, these particles display interchangeable surface functions, adaptable to different targets and applications. Our technology offers a defined, stable and programmable alternative to agricultural fungicides, with long-term perspectives in human health and heritage protection. We are seeking industrial, scientific and financial partners to accelerate the validation, industrialization and deployment of this approach.

  Maturity: POC
  Fundraising: Pre-Seed
  Keywords: biocontrol, virus, antifungal, synthetic biology, fungus, agriculture

  

   

• Hybrigenics Services

  #Ag/Clean/GreenTech #Diagnostic #Healthtech

  Hybrigenics Services provides life science R&D and contract research using advanced screening platforms to identify and characterize protein interactions, support drug discovery (mechanism of action, molecular glues), and select and optimize synthetic single-domain antibodies for research, diagnostic, or therapeutic use. Its Y2H platform includes extensive cDNA libraries (135+, 45 species) and an E3 ligase library, with exhaustive screening and integrated bioinformatics. The company also offers a widely published humanized synthetic VHH library for nanobody selection. With 3000+ clients and 700+ publications, it supports projects from study design to data analysis

  Maturity: POC (bioeconomy) – Preclinical (Health)
  Keyword: Biotech or Pharma, Therapeutic R&D, Food & agriculture, Animal health, Technology platforms, CRO

  

• Ispiron

  #Healthtech

  Ispiron Biotechnologies specializes in the scientific and technical development of innovative bioprocesses for the industrial production of therapeutic molecules. The company’s first product is a next-generation bioreactor designed to meet the needs of the pharmaceutical industry.

  Fundraising: Seed
  Keywords: Biotech, industrial & environmental, Biotech or pharma, animal health, Biotech or pharma, therapeutic R&D, Medical device or technology

  

• Lamark Biotech

  #Healthtech

  LAMARK develops innovative biotherapeutic formulations to support sustainable & affordable healthcare systems globally. The company’s technology platform allows for the development of thermostable, highly concentrated, protein formulations with extended shelf life at RT. Here we develop an integrin inhibitor (LCT) formulation with sustained-release properties for patients resistant to anti-VEGF treatments.

  Maturity: Preclinical
  Fundraising: Seed
  Keywords: Ophthalmology, retinal disease, wet and dry AMD, front of the eye disease, diabetes ocular complications

  

• Nutropy

  #Foodtech

  Nutropy is a French B2B startup developing animal-free dairy through precision-fermentation caseins. Its plug-and-play milk replacement fits existing dairy processes and enables products with the taste, texture and functionality of conventional dairy. With expertise in micelles and functionalization, Nutropy’s lead strain already exceeds the best known casein benchmark by 4x+, helping build a more sustainable and resilient dairy supply.

  Maturity: Pilot prototype
  Fundraising: Serie A
  Keywords: Biotech, Food & Agriculture

• ORAGEN THERAPEUTICS

  #Healthtech

  Oragen Therapeutics is a preclinical stage biotech addressing the $30B+ IBD market with ORA-251, a first-in-class oral RNA therapy derived from its proprietary technology enabling targeted oral delivery of nucleic acids. While current treatments rely on systemic injections with significant side effects, ORA-251 delivers precision gene-silencing directly to the gut. This breakthrough is powered by a proprietary platform already validated in preclinical models to achieve rapid remission. By combining a high-value lead asset with a versatile delivery engine, Oragen creates multiple pathways to a high-impact strategic exit.

  Maturity: Preclinical
  Fundraising: Serie A
  Keywords: Gene therapy, RNA, IBD

• ORINOVA

  #Healthtech

  ORINOVA is developing a breakthrough innovation in oncology with a patented nanomedicine incorporating a unique dual therapy: a chemotherapy molecule combined with gold nanoparticles. This combination amplifies the effect of radiotherapy, optimises the efficacy of chemotherapy and enables tumours to be targeted via intra-tumoral administration, thereby limiting side-effects for patients. This intelligent nano-object could revolutionise the treatment of particularly resistant solid tumours, such as glioblastoma. We are looking for preseed and seed investors and pharma partners for licensing.

  Maturity: Non-regulatory preclinical
  Fundraising: Pre-Seed
  Keywords: Oncology

  

• PAPILIO.BIO

  #Diagnostic

  At Papilio.bio, , we push the boundaries of diagnostics to create a silent revolution: the first HPV self-test basend on a new proprietary technology with laboratory-level sensitivity, delivering results in 15 minutes, all guided by an intuitive digital app. Our mission? To develop the next generation of rapid tests that turn a medical act into an everyday gesture without sacrificing reliability.

  Maturity: POC
  Fundraising: Pre-Seed
  Keywords: Precision Diagnostics

  

• PHAIRILAB

  #Healthtech

  PHAIRILAB innovates with unique biotechnological solutions focused on Colombian biodiversity. Our uniqueness lies in transforming natural resources into high-quality health products, principally focus on cancer patients. We seek collaborations for funding, R&D, licensing, industrialization, and commercialization of our discoveries. Together, we can revolutionize the bioeconomy and provide sustainable and effective health solutions globally. Join us in harnessing the immense potential of nature for the benefit of humanity.

  Maturity: Pilot Prototype (Bioeconomy), Clinical (Health)
  Fundraising: Seed
  Keywords: Biotech or pharma, animal health;Biotech or pharma, therapeutic R&D

  

• PREDIDIAB

  #Diagnostic

  PREDIDIAB proposes to develop tests capable of integrating all individual, environmental and heritable factors, to predict with good accuracy the onset of type 2 diabetes in subjects still in perfect apparent health, the age of onset, the form of diabetes and its evolution. This kind of prediction will enable us to propose a personalized prevention strategy. The tests are based on several patents filed or in preparation by academic players CERITD and UMR8199.

  Maturity: POC
  Fundraising: Seed
  Keywords: Biotech or pharma, therapeutic R&D, Diagnostics

  

• SE THERAPEUTICS

  #Healthtech

  SE-Therapeutics harnesses the power of certain microbial proteins to create innovative treatments. We created Self Entering forms of CRISPR/Cas proteins that can penetrate a wide variety of cells, paving the way for a new class of gene-editing therapeutics for the cell and gene therapy industry. Our primary mission is to enable access to life saving cell therapies in the field of oncology to millions of people.

  Maturity: Preclinical
  Fundraising: Seed
  Keywords: Biotech or pharma, therapeutic R&D

• Skite Solar

  #Ag/Clean/GreenTech

  Skite Solar develops perovskite-silicon tandem solar cells for space applications, targeting the €1.3B and fast-growing space-grade solar cell market. Our technology addresses perovskite’s key durability challenge in orbit, enabling higher efficiency, shorter lead times, and lower costs than incumbent III-V cells. We are seeking partnerships for R&D collaboration, in-orbit demonstration, and co-development with solar array manufacturers and satellite integrators, as well as pre-seed investors to fund our first in-space technology demonstration.

  Fundraising: Pre-Seed
  Keywords: Space, solar power, defense

• So Sweet

  #FoodTech

  SoSweet produces a new generation of sweet ingredients from plant proteins extracted through an innovative process to address sugar reduction and taste improvement challenges for food manufacturers.

  Fundraising: Seed
  Keywords: Biotech, Food & Agriculture

• SYNANTHRA

  #Ag/Clean/GreenTech

  Synanthra is a French deep-tech biotech reinventing how nitrogen fertiliser is made. We engineer bacteria to fix nitrogen from air, letting farmers produce biofertiliser on-farm and displace fossil-based synthetic nitrogen. Our unique bioelectrochemical platform repairs the broken nitrogen cycle at its source, just as Europe moves to decarbonise agriculture. We seek partners for financing, R&D, industrialisation, licensing and go-to-market.

  Maturity: Prototype Labo
  Fundraising: Pre-Seed
  Keywords: Ag/Clean/GreenTech, Industrial & Environmental

  

• SYNAPTYS neuroscience

  #Healthtech
  SYNAPTYS neuroscience is developing an innovative therapeutic approach that could transform the lives of Alzheimer’s patients. Our solution is one of the few to meet the new recommendations of experts. The combination of recent concordant studies supports our development program, which is expected to be launched in humans in 2028.

  Maturity: Preclinical
  Fundraising: Seed
  Keywords: Neurology, Alzheimer’s, Medication, R&D

  

• TERRABIOME TECHNOLOGIES

  #Ag/Clean/GreenTech #FoodTech

  TerraBiome Technologies develops microbiome-based solutions to assess and restore soil health, resilience, and agronomic performance. By combining DNA sequencing, advanced bioinformatics, and microbial expertise, the company helps farmers, turf managers, and landowners better understand and optimize soil biological functions. Its approach supports regenerative agriculture practices, reduces dependency on chemical inputs, and contributes to more sustainable and productive ecosystems.

  Maturity: POC
  Fundraising: Pre-Seed
  Keywords: Regenerative agriculture, reduction in the use of pesticides

  

• ZEBRAMED

  #Healthtech

  ZebraMed solves the human translatability gap of drug candidates (lack of efficacy, systemic toxicity). We industrialize whole-organism systemic data generation and, via our transparent AI XenoEx, humanize it to map human systemic response, discover new targets, and predict clinical outcomes. Our results are 2x closer to humans than in vitro, cutting time and costs by 50%. Seeking strategic collaborations for R&D, licensing, and our €1.5M pre-seed round.

  Keywords: Biotech or pharma, therapeutic R&D; AI, Foundational Data generation, AI pharma validation, AI drug discovery

  

3 min to Make an Impact!

Each day will feature a startup pitch competition showcasing approximately fifteen innovative companies aligned with the day’s theme.

With only 3 min to pitch, entrepreneurs will present their technologies and business potential to an expert jury composed of industry leaders, investors, Genopole representatives and partner incubators and support organizations.

The jury will select the startup demonstrating the strongest commercial potential and most compelling value proposition.

Prize for the Winners: tailored business development support through the Upscale Bio program, including qualified introductions and meetings with investors and major industry players.

• Industry Leaders

  

  Céline Triquel, Head of R&D Open innovation | Servier
  “Genopole Partnering Week is a key event that perfectly aligns with our strategy to actively support and nurture the biotech startup ecosystem through Spartners by Servier and BioLabs, our incubation initiatives, Servier Ventures, and many other programs dedicated to fostering innovation.
  The event provides a valuable opportunity to connect with high-potential companies supported by Genopole, whose projects consistently demonstrate a remarkable level of maturity and innovation.
  Several concrete collaborations have emerged from previous editions, which is undoubtedly the strongest proof of the value and impact of these interactions.
  We look forward to sharing insights into our areas of expertise, including oncology, neurology, and AI-driven precision medicine while remaining attentive to the breakthrough innovations that will shape the future of healthcare.
  Genopole Partnering Week is a unique opportunity to engage with some of the most promising innovators in the biotech ecosystem. It is an event not to be missed, and we are delighted to be participating once again this year.“

• Investors

  Constantin de Chaudenay, Senior Associate | AFI ventures
  “ We had the pleasure of participating in Genopole Partnering Week last year and are delighted to be back again this year.
  This event enables us to build valuable connections in just one day. At AFI Ventures, we support impact-driven startups from their earliest stages. Our ambition is to back founders developing concrete solutions to address the major challenges of our time, whether in health, climate, energy, pollution control, decarbonization, or new ways of producing and consuming.
  These are exactly the themes at the heart of the innovation ecosystem driven by Genopole.“

   

  

  Yves Loïc Martin, MAnager | Alternative Assets Finance
  “ One out of every two projects matches our investment strategy, which is significant. Our areas of interest include impact-driven innovation in energy, the environment, and sustainable materials, as well as healthcare, particularly oncology.
  Genopole Partnering Week features many projects aligned with these themes. We are looking for startups at the early-stage or pre-seed stage, sometimes through to seed round. The event gives us direct access to this type of company, led by bold entrepreneurs and well supported by the Genopole team.”

A complimentary round-trip shuttle service (bus) will be available between Paris (Porte d’Orléans) and Évry-Courcouronnes for access to and from the event.

🚨 Registration is open 🚨

Participation is free of charge, but registration is required.

Register now >>>

Venue:

GIP Genopole
20 rue Henri Desbruères
91000 Évry-Courcouronnes – France

📍How to get there on foot >>
📍How to get there by car >>

Contacts

For more information, please contact us at croissance@genopole.fr